ClinicalTrials.gg
RecruitingNCT07178314Updated Nov 17, 2026

At-Home Transcutaneous Tibial Nerve Stimulation for Overactive Bladder in Rural Women

An interventional study of Transcutaneous Tibial Nerve Stimulation (TTNS) in Overactive Bladder, sponsored by Oregon Health and Science University. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Oregon Health and Science University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Nov 17, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 333 studies in Urinary Bladder, Overactive with a site in United States — 40 open to participants now, 48 under way, 2 of them phase 3. Urinary Bladder, Overactive · United States.

Planned enrollment
178th of 288
38 · median 66
Started
2025
with 13 others
No phase
113 of 333
20 open now
Primary completion
2027-03
later than 26 of 47 live
Registered
317th of 333
by date

Among the 333 studies in Urinary Bladder, Overactive with a site in United States, this one is the 178th largest by planned enrollment of the 288 interventional ones that give a count, is one of 14 that started in 2025, is one of 113 with no phase, reaches primary completion later than 26 of the 47 other live ones, and was the 317th registered.

Urinary Bladder, Overactive

861 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.

Browse Urinary Bladder, Overactive studies →

Open to participants now

40 of the 333 studies in Urinary Bladder, Overactive with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 333 studies in Urinary Bladder, Overactive with a site in United States, or all of them as a file.
02

Study summary

This study contains a mixed-methods design consisting of a single-arm, interventional study and prospective patient interviews evaluating a novel self-implemented at-home Transcutaneous Tibial Nerve Stimulation (TTNS) treatment protocol for management of treatment naïve overactive bladder (OAB) among rural-dwelling women. This study will be conducted in 3 rural Oregon communities where Oregon Health \& Science University satellite campuses are located.

Read the detailed description

A total of 38 participants who meet the inclusion criteria will be recruited from clinical sites in three rural Oregon counties: 1) Klamath County, 2) Jefferson County, and 3) Coos County. Potential subjects with overactive bladder (OAB) who are being seen at healthcare clinics including primary care, obstetrics and gynecology, and pelvic floor physical therapy will be informed of this research study. Interested participants will be referred to the study coordinator via a flyer. Participants will be screened by phone and if deemed eligible and elect to participate, they will be consented over the phone/web platform. The participant has the option to sign a paper consent should they not have access to the internet. This will be mailed to them with prepaid postage for return of the signed consent. If a person does not elect to participate, the study team will offer the person information about behavioral modifications for treatment of overactive bladder and/or a referral to a local pelvic floor physical therapist. All communication and patient facing information will be offered in English or Spanish, utilizing Oregon Health \& Science University's (OHSU's) interpreter services for translation from English as described above.

Our intervention focuses on self-implemented at-home transcutaneous tibial nerve stimulation (TTNS) using a transcutaneous electrical nerve stimulation (TENS) unit. The TENS device is a nonsignificant risk device. A TENS unit with preset settings, labeled device, reusable electrodes, a battery, and detailed instructions will be mailed to the participant's designated address. All participants will receive a set of written instructions in the mail with details on skin preparation, application of the two electrodes to their ankle, connection of the electrodes to the TENS unit, standardized stimulation parameters, and adjustment of intensity to perception threshold. The written instructions will contain pictures and graphics that guide correct placement of the electrodes and use of the TENS unit settings. All participants will also be provided with a link to a short video demonstrating the application and use of the TENS unit. The script for this video is submitted with this IRB application.

Our protocol will instruct participants to use the TENS unit to deliver stimulation to the tibial nerve on one ankle for a 30-minute session, three times per week for 12 weeks starting treatment upon receipt of the device. The standardized stimulation parameters include pulse frequency of 10 Hz and pulse width of 200 ms, as used in previous studies. The intensity level is based on the participant's tolerance, ideally just above the perception threshold but not painful. Participants will be contacted by telephone at 2-3 week intervals to check on compliance with the protocol and address any issues. They will be given the study team's contact information to call sooner if questions or issues arise. Participants will also be provided with an electronic or printed 12 week calendar to keep track of completed sessions.

All participants recruited into the interventional study will also be approached and consented for possible involvement in individual interviews at their initial enrollment. Following completion of the intervention, the PI and co-investigator will use purposive sampling to identify 10-20 key informants for one-on-one video and/or audio recorded interviews with a member of the research group. Informants in the study sample are selected by investigators considering several parameters including demographic features, baseline and post-intervention scores on questionnaires from the primary and secondary outcomes previously mentioned, and compliance rate. Key informant interviews will provide insights on participant's unique experiences with self-managed TTNS at home, allowing for determination of patient perceived facilitators and barriers to this intervention. These key topics and themes can be used to inform future practices regarding self-implemented TTNS among rural dwelling patients.

A list of pre-determined, open-ended questions will be asked to each participant addressing different themes. The script and questions for the interview portion will be submitted alongside this proposal. Interviews will be recorded and transcribed verbatim using software licensed through the OHSU library (Dedoose). The software will be utilized to identify key themes emerging from the interview process. Data collection will cease once thematic saturation has been achieved, determined by the PI and co-investigator.

03

Conditions studied

  • Overactive Bladder

Keywords

  • Transcutaneous Tibial Nerve Stimulation (TTNS)
  • Rural Healthcare
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Rural residence (as defined by the Federal Office of Rural Health policy confirmed with the "Am I rural?" tool)
  • Clinical diagnosis of overactive bladder (OAB) with urinary frequency >= 8 times per day
  • Able to complete questionnaires, urination diaries, and interview in English or Spanish
  • Have reliable access to a telephone or email for communication
  • Ambulatory and able to use the toilet independently

Exclusion criteria

Exclusion Criteria:

  • Unable to consent
  • Pregnancy or planning to become pregnant during the study period
  • Previous treatment for OAB including medication, intravesical botox, and/or neuromodulation use
  • Presence of pacemaker or implantable defibrillator
  • Indwelling metal in both ankles
  • Presence of leg ulcers, open wounds, or skin conditions affecting lower legs
  • Absence of sensation in the lower legs
  • Active urinary tract infection
  • Predominantly stress urinary incontinence
  • Active
  • Neurogenic bladder
  • Subjective complaint of pelvic organ prolapse outside of vaginal introitus
  • Subjective symptoms of incomplete bladder emptying
  • Epilepsy
  • Peripheral artery disease affecting both legs
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    Rural Women Treated with Transcutaneous Tibial Nerve Stimulation

    Participants will undergo a self-implemented at-home Transcutaneous Tibial Nerve Stimulation (TTNS) treatment protocol for management of treatment naive overactive bladder (OAB) among rural dwelling women.

    Device: Transcutaneous Tibial Nerve Stimulation (TTNS)

Interventions

  • DeviceTranscutaneous Tibial Nerve Stimulation (TTNS)

    Participants will perform self-implemented at-home transcutaneous tibial nerve stimulation using a transcutaneous electrical nerve stimulation (TENS) unit. Participants will be instructed to use the TENS unit to deliver stimulation to the tibial nerve on one ankle for a 30-minute session, three times per week for 12 weeks upon receipt of the device. Intensity will be based on the participant's tolerance, just above the perception threshold but not painful.

    Also known as: TTNS, TENS Unit

06

What researchers measure

Primary outcomes

  1. Overactive Bladder questionnaire short form (OAB-q SF) Health-related Quality of life

    A 13-item survey assessing health-related quality of life. Assessed on a scale from 1 to 100 with a higher score representing a better quality of life.

    Time frame: Evaluated upon enrollment and following 12 weeks of intervention

  2. Overactive Bladder questionnaire short form (OAB-q SF) symptom bother

    A 13-item survey assessing symptom bother related to overactive bladder. Assessed on a scale from 1 to 100 with a higher score representing more bother, which is a worse outcome.

    Time frame: Evaluated upon enrollment and following 12 weeks of intervention

  3. 24-hour voiding frequency

    Mean 24-hour voiding frequency based on a 3-day voiding diary

    Time frame: 3-day voiding diary completed upon enrollment and following 12 weeks of intervention

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Mar 2027, 17 months after the start.

Of 135 non-industry interventional studies with no phase under Urinary Bladder, Overactive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 40. This study's planned 17 months is below that.

Counting every sponsor, half of 176 studies reached it within 19 months; a quarter within 10 and three quarters within 40.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Oct 2026 → Mar 2027 and completion Oct 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Sep 17, 2025
StartActual
Oct 6, 2025
Primary completionEst.
Mar 2027was Oct 2026
CompletionEst.
Mar 2027was Oct 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Mar 2027
Nov 17, 2026
Study completion
Oct 2026→Mar 2027
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Primary completion Oct 2026→Mar 2027
    Study completion Oct 2026→Mar 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07178314
Collaborators
American Urogynecologic Society
Responsible party
Sara Cichowski (Principal Investigator, Oregon Health and Science University) — Principal investigator
First posted
Sep 17, 2025
Start date
Oct 6, 2025
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Women's Health Research Unit Department of Ob/Gyn
Contact
whru@ohsu.edu
503-494-3666
Sara Cichowski
principal investigator · Oregon Health and Science University

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion